Press Releases

DEBx Medical, an Amsterdam-based innovative leader in advanced wound care, announces the successful completion of its second round of investment, led by TVM Capital Healthcare . The funding will accelerate DEBx Medical’s global expansion into key markets around the world. The investment follows a successful seed round of funding and reflects growing confidence in DEBx Medical’s innovative approach to treating chronic wounds, particularly through its breakthroug

Biometry Inc. (myBiometry), an asthma and COPD diagnostic and remote monitoring company, announced that it has successfully raised $5 million in an oversubscribed Seed funding round. The round was led by Dexcom Ventures, with participation from CareSource Indiana, Elevate Ventures, and other investor groups. This funding will advance the development of the company’s fenoTRACK solution, a breakthrough device designed to empower asthma and COPD patients by providing data to enable early d

Cooper University Health Care has selected NRC Health to be its partner in building Human Understanding across its network through humanized healthcare solutions and data-driven insights inline with Cooper’s mission: “To serve, to heal, to educate.” As a leading academic health system in southern New Jersey, Cooper serves more than two million patients every year, providing access to primary, specialty, tertiary, and urgent care in Southern New Jersey and Delaware

Avertix Medical, the developer of The Guardian® system - the world's first real-time, continuous heart attack detection and patient alerting system announced today that The Guardian System will conclude the three-year Medicare Transitional Pass-Through Payment (TPT) status at the end of this year. Effective January 1, 2025, under the Medicare Hospital Outpatient Prospective System, The Guardian will be fully reimbursed under APC 5224, with a national payment rate of $19,071. This tran

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employ

Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced that Butterfly iQ3™, its third-generation handheld ultrasound device, was the recipient of the Best Medical Technology Award at the 2024 Prix Galien USA Awards by the Galien Foundation. The Galien Foundation was established to foster and reward outstanding achi

RadNet, a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that ONRAD, Inc. (“ONRAD”), a national full-service radiology provider has selected RadNet’s DeepHealth OS to advance its next generation of radiology services. By utilizing the cloud-native and modular capabilities of DeepHealth OS, ONRAD will implement a customized solutions roadmap targeted to s

Lucid Diagnostics, a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second t

SeaStar Medical Holding Corporation, a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the receipt of a Breakthrough Device Designation from the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) for the Company’s patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) to treat chronic systemic inflammation in end-stage

Ontrak, a leading AI-powered and telehealth-enabled behavioral healthcare company, today announced a continuing expansion of its strategic partnership with Sentara Health Plans in the Commonwealth of Virginia. Ontrak is thrilled to be expanding services with Sentara Health Plans, the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system. This expansion represents a dual expansion of its Engage solution, a coaching-specific alternative